Liquid Biopsy News and reporting on cell-free DNA testing. Mar 17, 2023 Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics Mar 10, 2023 Guardant Health Submits Colorectal Cancer Screening Test to FDA for Premarket Approval Mar 9, 2023 Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial Mar 7, 2023 Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test Mar 6, 2023 Invitae's PCM Assay for Minimal Residual Disease Detection Nabs Coverage by Blue Shield of California Mar 2, 2023 Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana Mar 1, 2023 Biological Dynamics, OHSU Partner to Validate Pancreatic Cancer Early Detection Test Mar 1, 2023 CHLA Low-Pass WGS Liquid Biopsy Assay Could Aid Pediatric Cancer Diagnosis, Prognosis Premium Feb 23, 2023 Tempus, Actuate Therapeutics Ink Collaboration to Discover Biomarkers of Response for Elraglusib Feb 23, 2023 Lucence Liquid Biopsy Test to Receive Medicare Reimbursement in Lung Cancer Feb 16, 2023 Medicare to Cover Natera's Signatera MRD Test in Breast Cancer Feb 15, 2023 NeoGenomics Eyes Bladder Cancer as Future Indication for Radar MRD Test Premium Feb 15, 2023 Guardant Health to Study Impact of Shield Blood Test on Colorectal Cancer Screening Compliance Feb 13, 2023 Euformatics, ViennaLab, Oncompass Win European Liquid Biopsy Development Contract Feb 9, 2023 Startup mDetect Readying Trial of Methylation-Based Liquid Biopsy for Breast Cancers Premium Feb 8, 2023 UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer Feb 2, 2023 Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Feb 2, 2023 Universal DX Eyeing Approval for Colorectal Cancer Early Detection Test After Positive Data Premium Jan 26, 2023 Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors Premium Jan 24, 2023 New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions Premium Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma What's Popular? In Liquid Biopsy Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment Premium Medicare to Cover Natera's Signatera MRD Test in Breast Cancer Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics NeoGenomics Eyes Bladder Cancer as Future Indication for Radar MRD Test Premium
